{
    "organizations": [],
    "uuid": "9eee3f02a18cc1e0782fa166ac6ff72779e97c18",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fibrogen-gets-fda-fast-track-desig/brief-fibrogen-gets-fda-fast-track-designation-for-its-pancreatic-cancer-treatment-idUSASB0C8F1",
    "ord_in_thread": 0,
    "title": "FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - FibroGen Inc:\n* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER\n* FIBROGEN - FAST TRACK DESIGNATION FOLLOWS REVIEW OF COâ€™S PHASE 2 CLINICAL TRIAL EVALUATING PAMREVLUMAB IN COMBINATION WITH GEMCITABINE & NAB-PACLITAXEL Source text for Eikon:\n ",
    "published": "2018-03-02T02:53:00.000+02:00",
    "crawled": "2018-03-02T19:38:29.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fibrogen",
        "inc",
        "update",
        "fibrogen",
        "granted",
        "fast",
        "track",
        "designation",
        "fda",
        "pamrevlumab",
        "treatment",
        "patient",
        "locally",
        "advanced",
        "unresectable",
        "pancreatic",
        "cancer",
        "fibrogen",
        "fast",
        "track",
        "designation",
        "follows",
        "review",
        "co",
        "phase",
        "clinical",
        "trial",
        "evaluating",
        "pamrevlumab",
        "combination",
        "gemcitabine",
        "source",
        "text",
        "eikon"
    ]
}